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Abstract The possible correlation between DNA digestion and 
changes in nuclear morphology in apoptosis was studied by block- 
ing the apoptotic process at intermediate stages. The apoptogenic 
action of three drugs: etoposide, puromycin, tributyltin, was con- 
trasted with protease inhibitors with different specificity on U937 
cells. The inhibitors interfered with the development of the apop- 
totic features without shifting cell death to necrosis: treated cells 
showed abnormal morphologies, which could be recognized as 
intermediate stages of apoptosis; accordingly, DNA analysis 
showed an inhibitor-dependent block of the apoptotic DNA diges- 
tion. The comparison between size of DNA fragments and nuclear 
morphology suggested the following correlations: loss of normal 
nuclear shape with the appearence of a -2  Mb DNA band; 
ongoing chromatin condensation with the progressive DNA diges- 
tion up to 50 kb; nuclear fragmentation with DNA laddering. 
Protease inhibitors in etoposide-treated cells did not allow the 
formation of 700-300 kb fragments, suggesting that they possibly 
derive from a cell-mediated effect. 
Key words: Apoptosis; Proteases inhibitor; DNA digestion; 
Nuclear morphology; Etoposide 
I. Introduction 
Specific proteolytic events have been found to be involved in 
the process of apoptosis induced by many different stimuli. The 
Interleukin converting enzyme (ICE protease [1]), as well as 
proteases present in cytotoxic granules [2,3], when introduced 
and/or activated in the cell, are able to induce apoptosis; com- 
plementary, apoptosis may be blocked by specific protease in- 
hibitors [4]. While most proteins maintain their integrity in the 
apoptotic ells, several specific proteins have been shown to be 
proteolitically digested in apoptosis, such as nuclear lamins 
[5-7], fodrin [8], histone H1 [9], poly(ADP-ribose)polymerase 
[5,10]. Some of the proteases involved in apoptosis have been 
identified, such as calpain, a Ca2+-dependent cystein protease 
involved in cytoskeletal terations (i.e. blebbing) [11]; a novel 
24 kDa serine protease involved in the activation of the nucle- 
ase-dependent DNA digestion [12]; a protease involved in Fas- 
induced apoptosis [13]. 
*Corresponding author. Fax: (39) (6) 202 3500. 
Abbreviations: Mb, megabases; kb, kilobases; HMW, high molecular 
weight; FCS, foetal calf serum; PMC, puromycin; TBT, tributyltin; 
VP16, etoposide; TI, soy-bean trypsin inhibitor; PMSF, phenyl-methyl- 
sulphonyl-fluoride; IAA, iodoacetamide; NEM, N-ethyl-maleimide; 
TLCK: Na-p-tosyl-L-lysine chloromethyl ketone; TPCK, N-tosyl-e- 
phenylalanine chloromethyl ketone. 
The execution of the apoptotic process implies a chain of 
events which leads to the full development of the apoptotic 
features, such as DNA digestion into fragments of 200 base 
pairs and multiples (ladder), and nuclear fragmentation i  sev- 
eral membrane-bound vesicles [14,15]. 
DNA laddering is the final result of the progressive digestion 
of the cell genome carried on by several endonucleases [16]. 
They probably act following a hyerarchical order, producing 
at first well defined classes of High Molecular Weight (HMW) 
DNA fragments (300 and 50 kb), by a process dependent on 
proteolytic events [17], which may involve topoisomerases [18]. 
Later, DNA is further cleaved into the ladder. DNA digestion 
is not completed in some cell systems, intermediate stages being 
thus detectable [19]: in these instances a DNA ladder is not 
found, and the 50 kb fragments are instead accumulated. 
Also the changes in nuclear morphology are the result of a 
precise progression of events, implying in most instances the 
complete condensation of cell chromatin and its budding from 
the nuclear envelope [20]. This process is not completed in some 
cell systems, intermediate stages being thus detectable: in these 
instances masses of condensed chromatin in the form of cres- 
cents are located just within the nuclear envelope, without bud- 
ding [21]. 
A precise correlation between biochemical nd morphologi- 
cal events in apoptosis has not yet been made: the intermediate 
stages, which would help to analyze this correlation, are very 
unfrequent among cells induced to apoptosis, because the 
whole process is very rapid and starts asincronously [22], what- 
ever the inducer. In this study, we used protease inhibitors to 
block the apoptotic process at intermediate stages with the aim 
of correlating the events leading to nuclear fragmentation with 
those leading to chromatin digestion. 
2. Materials and methods 
2.1. Cell culture and treatments 
U937 cells were cultured in RPMI 1640 medium supplemented with 
10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin and streptomycin), 
and kept in a controlled atmosphere (5% CO2) incubator at 37°C. Cell 
viability has been assessed by Trypan blue exclusion. Induction to 
apoptosis: incubation for 4 h with: 10/lg/ml PMC; 1/tg/ml TBT; 100 
/lg/ml VP 16. Proteases inhibition: the inhibitors were added just before 
the apoptogenic treatment, and kept throughout the experiment (none 
of the inhibitors was cytotoxic within 24 h) at the following doses: TI, 
100/~g/ml; PMSF, 1 mM; IAA, 10/tM; NEM, 10/IM; TLCK, 50/tg/ml; 
TPCK, 50 ,ug/ml. 
2.2. Analysis and quantification of cell morphology and apoptosis 
At the end of each treatment, 2 x 105 cells were resuspended and fixed 
in 4% paraformaldeide, loaded on a gelatinized slide, stained with 
hematoxylin, and analyzed by direct optical microscopy. Apoptosis has 
been quantified by counting at least 100 cells in at least 3 random 
selected fields [23]. The abundance of each morphological class was 
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then estimated by counting at least 300 cells in at least 10 random 
selected fields. 
2.3. Analysis of DNA ladder 
2 x 10 6 cells were lysed in a buffer containing 10 mM EDTA, 100 mM 
Tris pH 8, 0.5% Sodium Lauroyl Sarkosine, 200/zg/ml proteinase K.
Nucleic acids were extracted by phenol-(chloroform/isoamylic alcohol 
24: I), ethanol precipitated, incubated in 100/zg/ml RNAse A 60' at 
37°C. The purified DNA from 2 × 106was loaded on a 1.5% agarose 
gel in TAE buffer, stained with 10/zg/ml ethydium bromide, and visu- 
alized on a 254 nM UV transilluminator. 
2.4. Pulsed field gel electrophoresis 
In the preparation of agarose plug, 106 cells were processed as de- 
scribed in [17]. Contour-clamped homogeneous electric field (CHEF) 
gel electrophoresis was carried out using the 'Gel Navigator' horizontal 
chamber and 'Pulsaphor' 2015 controller. Total run time was 19 h at 
180 V and 9 ° C. In particular: 180-s pulses for 4 h, 90-s pulses for 6 h, 
45-s pulses for 5 h and 20-s pulses for 4 h. 
3. Results 
3.1. Kinetics of VP16, PMC, TBT induced apoptosis 
Here described is the analysis of the apoptogenic action of 
three drugs acting on different cellular targets: etoposide 
(VP16), which inhbit opoisomerase II by stabilyzing the cleav- 
able complex [24], puromycin (PMC), which blocks protein 
synthesis by interfering with elongation [25], tributyltin (TBT), 
which interferes with protein, DNA and cytoskeleton structure 
[26]. These inducers have been chosen because they act on 
different argets, thus presumably inducing apoptosis with a 
different mechanism; moreover, apoptosis occurs rapidly and 
massively, concerning ---60% of cells within four hours (Fig. 1), 
so that at the end of the treatment the apoptotic ells have not 
yet degenerated. The full apoptotic morphology of U937 im- 
plies a strong cell blebbing and a heavy nuclear fragmentation, 
independently of the inducer. At early times of treatment, cells 
with abnormal morphologies are detected, albeit rarely: these 
cells recalls the intermediate stages of apoptosis as detected by 
ultrastructural analysis (Dini et al., submitted); they are quite 
rare, suggesting a very rapid evolution toward the final apop- 
totic morphology. 
3.2. Cells with intermediate apoptotic morphologies are detected 
upon apoptogenic treatments in the presence of  protease 
inhibitors 
A set of protease inhibitors with different specificities has 
been tested on U937; the doses have been chosen as the highest 
which did not alter cell viability within 24 h and not induce any 
gross morphological terations. The presence of protease in- 
hibitors during the apoptogenic treatments, reduced the extent 
of drug-induced apoptosis (Table 1). This was not due to a shift 
to cell death by necrosis, as monitored by the Trypan blue 
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Fig. 1. Kinetics of apoptosis. Apoptosis induced on U937 by VP16, 
PMC, TBT, has been quantified according to [23]. A typical experi- 
ments is shown among three (TBT) and > 10 (VP16 and PMC) per- 
formed. While TMT and PMC has an identical kinetics, VP16 is a 
slower inducer. 
exclusion test (Table 1): instead, at the end of treatment (4 h), 
the intermediate stages of apoptosis became very abundant, as 
though an inhibitor-dependent accumulation had occurred. 
Longer treatments allowed a small fraction of the intermediate 
stages to evolve into full apoptosis, while most cells remained 
frozen at the early steps: this suggests that protease inhibitors 
acted to block some apoptotic steps rather than slowing down 
the whole process. 
3.3. Progression through intermediate stages of apoptosis 
A transmission electron microscopy analysis of U937 in- 
duced to apoptosis upon many treatments allowed to describe 
a progression of events from normal to fully apoptotic ells 
(Dini et al., submitted), which is graphycally depicted in panel 
A of Fig. 2: normal cells, with relaxed chromatin and irregularly 
shaped nuclei (stage I); the nuclei loose the irregular shape 
becoming rounded, though maintaining the chromatin relaxed 
(stage II); then chromatin condenses progressively in patches 
at the nuclear edge (stage III); the patches bud from the nuceus 
to give fully apoptotic ells with fragmented nuclei (stage IV). 
The features considered inthe present analysis are only those 
which can be unambigously detected by optical microscopy 
Table 1 
Quantification fapoptotic and trypan blue excluding cells in the presence of protease inhibitors 
% Apoptotic ells Inducer only + NEM + IAA + PMSF + T.I. + TLCK + TPCK 
(% trypan blue excluding) 
VP16 66 (97) 4 (92) 2 (99) 48 (97) 58 (99) 28 (88) 3 (92) 
PMC 83 (99) 8 (99) 19 (88) 45 (95) 90 (99) 31 (99) 2 (89) 
TBT 86 (99) 9 (74) 21 (80) 67 (56) 84 (80) 82 (64) 3 (96) 
Apoptosis induced on U937 by VP16, PMC, TBT, in the presence of protease inhibitors, has been quantified according to [23]. In parentheses is 
the fraction of cells excluding trypan blue at the end of the treatment. One experiment (among > 5 performed) is shown, the same that has been analyzed 
for the DNA patterns. 
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3.4. Quantitative analysis of  cells at intermediate stages of 
apoptosis 
A quantitative analysis of the morphologies shown in Fig. 2 
has been performed for all apoptogenic treatments in the pres- 
ence of all protease inhibitors; Fig. 3 shows the results, as the 
fraction of cells belonging to each of the four categories (exper- 
iments with VP16 and PMC; TBT behavior overlaps that of 
PMC, with the difference that TLCK did not alter TBT's apop- 
togenic action, see Table 1). Upon VP16 treatment, a total 
(NEM) or partial but substantial (TLCK and IAA) rescue to 
perfectly normal cell morphology was found (Fig. 3a). This was 
not found upon PMC or TBT treatments (Fig. 3b): thus, 
TPCK, TLCK and IAA may block a very early step in VP16- 
induced apoptosis, which is not shared by TBT or PMC; alter- 
natively, they may inhibit a pre-apoptotic signalling event in 
response to the direct VP 16-induced DNA cleavage (see below). 
The most striking effect is observed, upon all three apopto- 
genic treatments, with TPCK (Fig. 3a and b): most cells show 
a normally relaxed chromatin but have lost the normal, irregu- 
lar nuclear shape, becoming rounded (stage II vs. stage I, see 
Fig. 2). This suggests that a first step towards apoptosis has 
been made, but TPCK has tightly blocked a function which is 
necessary in order to proceed to the next step (i.e. chromatin 
condensation). 
Cells with chromatin condensed at the nuclear periphery, 
without nuclear fragmentation (stage III: see Fig. 2) are also 
accumulated, mostly upon inhibition of cystein proteases 
(NEM and IAA, see Fig. 3). These cells, even though their 
chromatin has condensed, are not undergoing nuclear fragmen- 
tation, suggesting that cystein proteases have a role in nuclear 
fragmentation. 
Fig. 2. Progression from viable cells to apoptotic cells. (A) The drawing 
illustrates the progession to apoptosis as results from the electron mi- 
croscopy analysis of U937 induced to apoptosis (Dini et al., submitted). 
(B) Morphologies of U937 induced to apoptosis in the presence 
ofprotease inhibitors. (a) untreated cells: see the irregularly shaped nuc- 
lei (stage I); (b) PMC + TPCK: see most of the cells with rounded, 
sharply defined nuclei and non-condensed chromatin (stage II); 
(c) PMC + NEM; see cells with chromatin progressively condensing at 
the nuclear edge, at an early (empty arrow) and late (dark arrow) stage 
III; (d) PMC alone: see apoptotic ells with fragmented nuclei and 
compact chromatin (stage IV). 
upon nuclear staining, such as nuclear shape and gross chroma- 
tin condensation. According to these criteria, the abnormal 
morphologies detected upon apoptogenic treatments in the 
presence of protease inhibitors resemble the intermediate stages 
II and III. As an example, panel B of Fig. 2 shows untreated 
U937 (a) and U937 induced to apoptosis by PMC in the pres- 
ence of TPCK (b), NEM (c), and without protease inhibitors 
(d). The resemblance of cells in c with stage II, cells in d with 
early (empty arrows) and late (dark arrows) stage III, allows 
to hypothesize that a progression of events toward apoptosis 
has been inhibited by different protease inhibitors at different 
stages. 
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Fig. 3. Quantitative analysis of cells with normal, apoptotic and inter- 
mediate morphologies. The different morphologies have been quanti- 
fied at four hrs of treatment, asdescribed in materials and methods. The 
results how one experiment among four performed. Bars' values indi- 
cate the percentage of cells showing the corresponding morphology. 
A 3.5. Apoptotic DATA degradation is blocked at different stages 
by protease inhibitors 
PFGE analysis (Fig. 4a) shows that healthy U937 cells have 
only intact DNA, unable to enter the gel (lane C). Cells induced 
to apoptosis by VP16 have many classes of fragments: bands 
at ---2 Mb, 1.3 Mb, 700, 300, and 48 kb (indicated by the closed 
triangles in Fig. 4a, VP16, lanes '0'), and a smear of < 50 kb. 
Upon PMC and TBT treatments, only the 2Mb and 48kb band 
and the lower smear are clearly detectable, while the others are 
very faint (closed triangles in Fig. 4a, PMC lanes '0'; the pattern 
obtained with TBT is identical with the exception that TLCK 
did not inhibit apoptotic DNA digestion). The degree of DNA 
digestion is reduced by all protease inhibitors but tripsin inhib- 
itor. Strikingly, upon all apoptogenic treatments, in the pres- 
ence of TPCK (lane 7 on Fig. 4a and b) DNA is cleaved to form 
the -> 2 Mb band, whereas any further digestion into smaller 
molecules is inhibited. 
In the presence of cystein protease inhibitors (NEM and 
IAA), the whole set of fragments up to 50 kb are formed, while 
the smear of lower fragments (corresponding to the DNA lad- 
der) is very faint: the nuclease responsible for ladder formation 
seems thus not working. 
DNA from treated cells has also been analyzed by conven- 
tional electrophoresis on 1.2% agarose gel. A DNA ladder has 
been found in all treatments which led to the < 50 kb smear, 
thus confirming PFGE analysis. Fig. 4b shows the DNA pat- 
tern upon four exemplificative treatments, the same which have 
been shown in Fig. 2B to induce four different morphological 
types: PMC alone (lane 0); PMC + NEM; PMC + TPCK; con- 
trol cells: a ladder is clear in PMC, very faint or undetectable 
in the presence of NEM and TPCK. 
The comparison between DNA digestion and nuclear mor- 
phological changes in apoptosis upon protease inhibition sug- 
gests that cells at stage II have the DNA cleaved up to the -> 2 
Mb band, while cells at stage III show the DNA HMW frag- 
ments but not the DNA ladder; fully apoptotic ells (stage IV) 
show nuclear fragmentation a d DNA ladder; no exception is 
found by comparing data in Fig. 2 with Fig. 4. The clearest 
observations in support o this correlations are the following: 
TPCK in all apoptogenic treatments blocked the progression 
of DNA digestion at the -> 2 Mb band (Fig. 4a and b), concom- 
itantly blocking chromatin condensation (Fig. 2); NEM and 
IAA accumulated cells at stage III and inhibited DNA ladder- 
ing but not HMW fragments formation; TLCK on PMC lead 
to the presence of cells at stage II, III and IV, and the DNA 
pattern show fragments of any size, from >-2 Mb up to the 
DNA ladder. 
3.6. VP16-induced DNA fragmentation i  700-300 kb is 
probably cell-mediated 
The 2Mb band, by the conditions used in the PFGE analysis 
described here, is the result of the accumulation of fragments 
measuring -> 2 Mb (i.e. PFGE protocols more suitable for very 
large DNA fragments might allow to resolve it into more 
bands). This band, which is very intense upon VP 16 treatments 
(Fig. 4a), may originate, in addition to the early apoptotic 
digestion, also from the DNA damage caused irectly by VP 16. 
In the presence of TPCK (lane 7) and NEM (lane 2), no mole- 
cules smaller than 2 Mb are detectable: since the inhibitors 
block the DNA cleavage in 700 and 300 kb HMW fragments, 
it is likely that these fragments do not originate from the DNA 
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Fig. 4. DNA analysis. The results from one experiment is shown among 
two complete xperiments performed. (A) Pulsed field gel electrophore- 
sis analysis: closed triangles indicate the bands resulting from DNA 
digestion upon treatments with inducer only, as described in the text 
(0 = inducer only; S. cerevisiae: commercially available size marker 
spanning from 2200 to 225 kb; 3. = undigested 3. genome, 50 kb). 
(B) Conventional garose gel electrophoresis. Analysis of DNA ladder 
upon induction to apoptosis with protease inhibitors: exemplificative 
treatments giving a significant difference among each other are shown. 
damage caused directly by VP16 action on topoisomerase II,
but are instead mediated by a further cellular function. 
4. Discussion 
Before discussing the results, some preliminary considera- 
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tions may help to define the scope of this study. The experi- 
ments have been performed on living cells: this did not allow 
the use of the specific but cell-unpermeable p ptide-based pro- 
tease inhibitors; moreover, the doses of the less specific cell- 
permeable inhibitors had to be kept below toxicity, and might 
then be not sufficient for a complete nzymatic inhibition: thus 
TPCK, which could be used at high concentrations, tightly 
blocked the progression of apoptosis, while NEM or IAA, 
necessarily used at very low concentrations, lead to 'leaky' 
blocks. The presence of a tight block may have obscured the 
presence of a second block at a downstream step. In our system, 
serine and cystein protease inhibitors in some instances pro- 
duced overlapping effects; on the other hand, serine proteases 
exerted effects which differed among each other (i.e. compare 
TPCK and PMSF): this may be explained because ach inhib- 
itor acts on its own set of enzymes, and overlapping effects are 
to be expected. Some difference in the behavior of protease 
inhibitors on the three apoptogenic treatments (i.e. NEM res- 
cued to healthy cell morphology VP16 treated cells, while 
blocking PMC and TBT treated cells at stage III) might be due 
to a difference in the mechanism of induction to apoptosis. The 
same may apply for the different pattern of HMW fragments 
in PMC and TBT vs. VP16 treated cells, since only the latter 
showed the 1300, 700 and 300 kb bands. 
The present study was aimed to analyze the correlation be- 
tween the morphological changes occurring in the nuclei of 
apoptotic ells and the progression of DNA digestion, which 
was allowed by the finding that protease inhibitors induced the 
accumulation of cells at intermediate stages of apoptosis. This 
is in line with the concept of apoptosis as a 'programmed' chain 
of interdependent events occurring in a defined temporal se- 
quence, and not a catastrophic process. While the involvement 
of proteases in apoptotic DNA digestion has been clearly as- 
sessed [12,17], a similar approach to nuclear morphology is 
lacking so far. The comparison between size of DNA fragments 
and nuclear morphology allowed to establish a 'temporal' asso- 
ciation between uclear and DNA changes occurring in apop- 
tosis: the loss of normal nuclear shape with the appearence of
a -> 2Megabases DNA band; ongoing chromatin condensation 
with the progressive DNA digestion up to 50 kb; nuclear frag- 
mentation with DNA laddering. Though clear, these correla- 
tions have been obtained by using not very specific protease 
inhibitors, which may interfere with other cellular functions 
unrelated to proteolysis (i.e. NEM is a powerful thiol alkylating 
agent): thus, it would be interesting to challange these correla- 
tions with more natural events. A 'naturally occurring' accumu- 
lation at intermediate stages has been reported in hepatocytes 
treated with TGFlf l  [21]: chromatin condenses in the absence 
of nuclear fragmentation, and no DNA ladder is detectable. 
Other findings describe that nuclear fragmentation can occur 
also in the absence of a DNA ladder in epithelial [19] and 
lymphoid cells ([27] and M. Marini, personal communication): 
systems not so 'well equipped' for apoptosis as U937 cells, may 
lack the functions (enzymes?) necessary to undergo some of the 
late events in apoptosis (i.e. absence of DNAse I [7]). 
A possible link between the apoptotic hanges in nuclear 
morphology and DNA digestion is the fate of the nuclear lam- 
ins, which have been found to be proteolytically degraded in 
apoptosis [5-7]: the analysis of the function of nuclear lamins 
in healthy cells suggests that lamin breakdown could be in- 
volved in both nuclear re-shaping and apoptotic hromatin 
fragmentation. Nuclear lamins digestion has indeed been 
shown to occur both at the beginning and during apoptosis, 
being probably involved in chromatin condensation [28] 
VP16 induces two types of DNA cleavage in whole cells: 
direcly by the stabilization the cleavable complexes created by 
topoisomerase II; and indirectly by the activation of the apop- 
totic nucleases. DNA fragments of 700 and 300 kb are detected 
by PFGE in in vivo (whole cell) experiments soon after VP16 
exposure: they are believed to be a direct effect of the drug- 
enzyme interaction and not a sign of ongoin apoptosis, because 
they form also when apoptosis i inhibited (i.e. by actinomycin 
D, [24]) and reseal upon drug removal (while apoptosis is irre- 
versible [29]). In our system, TPCK and NEM inhibit the for- 
mation of the 700 and 300 kb fragments: this (unless both 
TPCK and NEM directly block topoisomerase II before the 
formation of the cleavable complex, thereby eliminating VP16 
target) suggests that they are not the direct effect of VP16 
cleavage, but the result of a cell-mediated response to VP16, an 
early signalling event which stops when the drug is removed. 
The nature of the unknown signalling event which triggers 
apoptosis in response to VP16-induced DNA damage, hypthe- 
sized by many authors, might be a proteolysis: indeed, NEM, 
and partially IAA and TLCK, which inhibited VP16 apopto- 
genic action ab initio both at the morphological nd DNA level, 
may have interfered with such early signalling. 
Acknowledgements: V.M. is a recipient of a fellowship from 'Scuola di 
Specializzazione in Biotecnologie' by Montedison, whose grant has 
supported the cost of this research. 
References 
[1] Miura, M., Zhu, H., Rotello, R., Hartwieg, E.A., Yuan, J. (1993) 
Cell 75, 653-660. 
[2] Shi, L., Kam, C.M., Powers, J.C., Aebersold, R., Greenberg, A.H. 
(1992) J. Exp. Med. 176, 1521-1529. 
[3] Shi, L., Kraut, R.P., Aebersold, R., Greenberg, A.H. (1992) 
J. Exp. Med. 175, 553-566. 
[4] Sarin, A., Adams, D.H., Henkart, P.A. (1993) J. Exp. Med. 178, 
1693-1700. 
[5] Kaufmann, S.H. (1989) Cancer Res. 49, 5870-5878. 
[6] Lazebnik, Y.A., Cole, S., Cooke, C.A., Nelson, W.G., Earnshow, 
W.C. (1993) J. Cell Biol. 123, 7-22. 
[7] Ucker, D.S., Obermiller, P.S., Eckart, W., Apger, J.R., Berger, 
N.A., Meyers, J. (1992) Mol. Cell Biol. 12, 306~3069. 
[8] Martin, S.J., O'Brien, G.A., Nishioka, W.K., McGahon, A.J., 
Mahboubi, A., Saido, T.C., Gree, D.R. (1995) J.Biol. Chem. 270, 
6425-6428. 
[9] Gaziev, A.I., Kutsyi, M.P. (1992) Int. J. Radiat. Biol. 61, 
pp. 169-174. 
[10] Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson,.E., 
Poirier, G.G. (1993) Cancer Res. 53, 3976-3985;. 
[11] Squier, M.K., Miller, A.C., Malkinson, A.M., Cohen, J.J. (1994) 
J. Cell Physiol. 159, 229 237. 
[12] Wright, S.C., Wei, Q.S., Zhong, J., Zheng, H., Kinder, D.H., 
Larrick, J.W. (1994) J. Exp. Med. 180, 2113-2123. 
[13] Schlegel, J., Peters, I., Orrenius, S. (1995) FEBS Lett. 364, 139- 
142. 
[14] Wyllie, A.H. (1987) J. Pathol. 153, 313-316. 
[15] Wyllie, A.H. (1980) Nature 284, 555 558. 
[16] Peitsch, M.C., Mannherz, H.G., Tschopp, J. (1994) Trends Cell 
Biol. 4, 37-41. 
[17] Zhivotovsky, B., Wade, D., Gahm, A., Orrenius, S., Nicotera, P. 
(1994) FEBS Lett. 351, 150-154. 
[18] Kataoka, A., Kubota, M., Wakazono, Y., Okuda, A., Bessho, R., 
Wei Lin, Y., Usami, I., Akyiama, Y., Furusho, K. 1995 FEBS Lett. 
364, 264-267. 
[19] Oberhammer, F., Wilson, J.W., Dive, C., Morris, I.D., Hickman, 
14 L. Ghibelli et aL /FEBS Letters 377 (1995) 9-14 
J.A., Wakeling, A.E., Walker, ER., Sikorska, M. (1993) EMBO 
J. 12, 3679 3684. 
[20] Falcieri, E., Zamai, L., Santi, S., Cinti, C., Gobbi, P., Bosco, D., 
Cataldi, A., Betts, C., Vitale, M. (1994) Hisochemistry 102, 221- 
231. 
[21] Oberhammer, F., Fritsch, G., Schmied, M., Pavelka, M., Printz, 
D., Purchio, T., Lassmann, H., Schulte-Hermann, H. (1993) J. Cell 
Sci. 104, 317-326. 
[22] Evan, G.I., Wyllie, A.H., Gilbert, G.S., Littlewood, T.D., Land, 
H., Brooks, M., Waters, C.M., Penn, L.Z., Hancock, D.C. (1992) 
Cell 69, 119-128. 
[23] Nosseri, C., Coppola, S., Ghibelli, L. (194) Exp. Cell Res. 212, 
367-373. 
[24] Walker, RR., Smith, C., Youdale, T., Leblanc, J., Whitfield, J.F., 
Sikorska, M. (1991) Cancer Res. 51, 1078-1085. 
[25] Chow, S.C., Peters, I., Orrenius, S. (1995) Exp. Cell Res. 216, 
149-159. 
[26] Chow, S.C., Kass, G.E., McCabe, M.J., Orrenius, S. (1992) Arch. 
Biochem. Biophys. 298, 143-149. 
[27] Falcieri, E., Martelli, A.M., Bareggi, R., Cataldi, A., Cocco, L. 
(1993) Biochem. Biophys. Res. Commun. 193, 19-25. 
[28] Oberhammer, F.A., Hochegger, K., Froschl, G., Tiefenbacher, R., 
Pavelka, M. (1994) J. Cell Biol. 126, 827-837. 
[29] Filipski, J., Leblanc, J., Youdale, T., Sikorska, M., Walker, ER. 
(1990) EMBO J. 9, 1319-1327. 
